Literature DB >> 8430940

Inhibition of lipopolysaccharide-induced macrophage tumor necrosis factor-alpha synthesis by polymyxin B sulfate.

C P Coyne1, B W Fenwick.   

Abstract

The antibiotic polymyxin B sulfate is a cationic polypeptide with a unique cyclical configuration and distinct cationic characteristics. In this investigation, polymyxin B was evaluated to determine its ability to prevent synthesis of lactic acid and tumor necrosis factor-alpha (TNF-alpha) by lipopolysaccharide-stimulated strain RAW 264.7 macrophage-like cell populations. In this context, gradient concentrations of polymyxin B were formulated in the presence of fixed concentrations of lipopolysaccharide fractions from Escherichia coli (B4:0111), E coli (J5), Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella minnesota, and S typhimurium (Re). Quantitation of TNF-alpha was established by the application of a tissue culture-based biological assay system, using the WEHI 164 clone 13 indicator cell line. Investigations also included evaluation of the ability of gradient concentrations of lipopolysaccharide fractions from E coli (B4:0111), E coli (J5), K pneumoniae, P aeruginosa, S minnesota, and S typhimurium (Re) to form a complex with polymyxin B. This was established through application of high-performance thin-layer chromatography techniques. On the basis of the known molecular characteristics of lipopolysaccharide, its lipid A-core subfractions, and polymyxin B, these results imply that cytoprotective properties of polymyxin B are attributable to direct interaction and subsequent complex formation. More specifically, the mechanism by which polymyxin B exerts affinity for lipopolysaccharide fractions is proposed to occur through attractive ionic interactions established between the cationic diaminobutyric acid residues of polymyxin B and the mono- or diphosphate group(s) of the lipid A-core moiety. It is highly probable that this molecular phenomenon is accompanied by hydrophobic interactions established between the terminal methyloctanoyl or methylheptanoyl groups of polymyxin B and the saturated carbon chains of the lipid A-core subfraction of lipopolysaccharide fractions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8430940

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

Review 1.  Potential virulence factors of Proteus bacilli.

Authors:  A Rózalski; Z Sidorczyk; K Kotełko
Journal:  Microbiol Mol Biol Rev       Date:  1997-03       Impact factor: 11.056

2.  Influence of synthetic antiendotoxin peptides on lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14.

Authors:  A Iwagaki; M Porro; M Pollack
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

3.  Circulating monocytes in patients with acute coronary syndromes lack sufficient interleukin-10 production after lipopolysaccharide stimulation.

Authors:  P L van Haelst; J W Cohen Tervaert; J Bijzet; C Baljé-Volkers; J F May; B Langeveld; R O B Gans
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

4.  Unusual interaction of a lipopolysaccharide isolated from Burkholderia cepacia with polymyxin B.

Authors:  Hirofumi Shimomura; Motohiro Matsuura; Shinji Saito; Yoshikazu Hirai; Yasunori Isshiki; Kazuyoshi Kawahara
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

5.  Differential regulation of membrane CD14 expression and endotoxin-tolerance in alveolar macrophages.

Authors:  Shu-Min Lin; Charles W Frevert; Osamu Kajikawa; Mark M Wurfel; Kimberly Ballman; Stephen Mongovin; Venus A Wong; Amy Selk; Thomas R Martin
Journal:  Am J Respir Cell Mol Biol       Date:  2004-04-01       Impact factor: 6.914

6.  Houttuyniacordata Thunb. polysaccharides ameliorates lipopolysaccharide-induced acute lung injury in mice.

Authors:  Yan-Yan Xu; Yun-Yi Zhang; Ying-Ye Ou; Xiao-Xiao Lu; Ling-Yu Pan; Hong Li; Yan Lu; Dao-Feng Chen
Journal:  J Ethnopharmacol       Date:  2015-07-17       Impact factor: 4.360

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.